Roche Welcomes FDA Approvals for Injectable Versions of MS and Cancer Drugs

The US FDA has authorised injectable iterations of Roche’s multiple sclerosis and cancer biologic treatments. The approval means the MS drug Ocrevus Zunovo and the cancer drug Tecentriq Hybreza can be administered through a subcutaneous injection. As such, these versions can be administered significantly faster than their IV counterparts. The drugs, manufactured incorporating Halozyme Therapeutics’ Enhanze delivery technology, are being sold in more than 50 nations under a different name.